Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma

Kostin, Alexander I. ; Lundgren, Maria N. ; Bulanov, Andrey Y. ; Ladygina, Elena A. ; Chirkova, Karina S. ; Gintsburg, Alexander L. ; Logunov, Denis Y. ; Dolzhikova, Inna V. ; Shcheblyakov, Dmitry V. and Borovkova, Natalia V. , et al. (2021) In Vox Sanguinis 116(6). p.665-672
Abstract

Background and objectives: COVID-19 convalescent plasma is an experimental treatment against SARS-CoV-2. The aim of this study is to assess the impact of different pathogen reduction methods on the levels and virus neutralizing activity of the specific antibodies against SARS-CoV2 in convalescent plasma. Materials and methods: A total of 140 plasma doses collected by plasmapheresis from COVID-19 convalescent donors were subjected to pathogen reduction by three methods: methylene blue (M)/visible light, riboflavin (R)/UVB and amotosalen (A)/UVA. To conduct a paired comparison, individual plasma doses were divided into 2 samples that were subjected to one of these methods. The titres of SARS-CoV2 neutralizing antibodies (NtAbs) and levels... (More)

Background and objectives: COVID-19 convalescent plasma is an experimental treatment against SARS-CoV-2. The aim of this study is to assess the impact of different pathogen reduction methods on the levels and virus neutralizing activity of the specific antibodies against SARS-CoV2 in convalescent plasma. Materials and methods: A total of 140 plasma doses collected by plasmapheresis from COVID-19 convalescent donors were subjected to pathogen reduction by three methods: methylene blue (M)/visible light, riboflavin (R)/UVB and amotosalen (A)/UVA. To conduct a paired comparison, individual plasma doses were divided into 2 samples that were subjected to one of these methods. The titres of SARS-CoV2 neutralizing antibodies (NtAbs) and levels of specific immunoglobulins to RBD, S- and N-proteins of SARS-CoV-2 were measured before and after pathogen reduction. Results: The methods reduced NtAbs titres differently: among units with the initial titre 80 or above, 81% of units remained unchanged and 19% decreased by one step after methylene blue; 60% were unchanged and 40% decreased by one step after amotosalen; after riboflavin 43% were unchanged and 50% (7%, respectively) had a one-step (two-step, respectively) decrease. Paired two-sample comparisons (M vs. A, M vs. R and A vs. R) revealed that the largest statistically significant decrease in quantity and activity of the specific antibodies resulted from the riboflavin treatment. Conclusion: Pathogen reduction with methylene blue or with amotosalen provides the greater likelihood of preserving the immunological properties of the COVID-19 convalescent plasma compared to riboflavin.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
amotosalen, COVID-19 convalescent plasma, methylene blue, NtAbs, pathogen reduction, riboflavin
in
Vox Sanguinis
volume
116
issue
6
pages
665 - 672
publisher
Wiley-Blackwell
external identifiers
  • pmid:33734455
  • scopus:85102624413
ISSN
0042-9007
DOI
10.1111/vox.13056
language
English
LU publication?
yes
id
c9618d05-845c-42cd-9b99-0782d38e361a
date added to LUP
2021-03-29 13:04:09
date last changed
2024-05-18 07:09:14
@article{c9618d05-845c-42cd-9b99-0782d38e361a,
  abstract     = {{<p>Background and objectives: COVID-19 convalescent plasma is an experimental treatment against SARS-CoV-2. The aim of this study is to assess the impact of different pathogen reduction methods on the levels and virus neutralizing activity of the specific antibodies against SARS-CoV2 in convalescent plasma. Materials and methods: A total of 140 plasma doses collected by plasmapheresis from COVID-19 convalescent donors were subjected to pathogen reduction by three methods: methylene blue (M)/visible light, riboflavin (R)/UVB and amotosalen (A)/UVA. To conduct a paired comparison, individual plasma doses were divided into 2 samples that were subjected to one of these methods. The titres of SARS-CoV2 neutralizing antibodies (NtAbs) and levels of specific immunoglobulins to RBD, S- and N-proteins of SARS-CoV-2 were measured before and after pathogen reduction. Results: The methods reduced NtAbs titres differently: among units with the initial titre 80 or above, 81% of units remained unchanged and 19% decreased by one step after methylene blue; 60% were unchanged and 40% decreased by one step after amotosalen; after riboflavin 43% were unchanged and 50% (7%, respectively) had a one-step (two-step, respectively) decrease. Paired two-sample comparisons (M vs. A, M vs. R and A vs. R) revealed that the largest statistically significant decrease in quantity and activity of the specific antibodies resulted from the riboflavin treatment. Conclusion: Pathogen reduction with methylene blue or with amotosalen provides the greater likelihood of preserving the immunological properties of the COVID-19 convalescent plasma compared to riboflavin.</p>}},
  author       = {{Kostin, Alexander I. and Lundgren, Maria N. and Bulanov, Andrey Y. and Ladygina, Elena A. and Chirkova, Karina S. and Gintsburg, Alexander L. and Logunov, Denis Y. and Dolzhikova, Inna V. and Shcheblyakov, Dmitry V. and Borovkova, Natalia V. and Godkov, Mikhail A. and Bazhenov, Alexey I. and Shustov, Valeriy V. and Bogdanova, Alina S. and Kamalova, Alina R. and Ganchin, Vladimir V. and Dombrovskiy, Eugene A. and Volkov, Stanislav E. and Drozdova, Nataliya E. and Petrikov, Sergey S.}},
  issn         = {{0042-9007}},
  keywords     = {{amotosalen; COVID-19 convalescent plasma; methylene blue; NtAbs; pathogen reduction; riboflavin}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{665--672}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Vox Sanguinis}},
  title        = {{Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma}},
  url          = {{http://dx.doi.org/10.1111/vox.13056}},
  doi          = {{10.1111/vox.13056}},
  volume       = {{116}},
  year         = {{2021}},
}